NO20063230L - CRF receptorantagonister og fremgangsmater for fremstilling derav - Google Patents

CRF receptorantagonister og fremgangsmater for fremstilling derav

Info

Publication number
NO20063230L
NO20063230L NO20063230A NO20063230A NO20063230L NO 20063230 L NO20063230 L NO 20063230L NO 20063230 A NO20063230 A NO 20063230A NO 20063230 A NO20063230 A NO 20063230A NO 20063230 L NO20063230 L NO 20063230L
Authority
NO
Norway
Prior art keywords
crf receptor
receptor antagonists
methods
preparation
crf
Prior art date
Application number
NO20063230A
Other languages
English (en)
Inventor
Deborah Slee
Zhiyong Luo
John Edward Tellew
John Williams
Xiaohu Zhang
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20063230L publication Critical patent/NO20063230L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives CRF reseptorantagonister som firmer anvendelse ved behandling av et antall forstyrrelser inkludert behandling av forstyrrelser som manifesterer hypersekresjon av CRF i varmblodige dyr, for eksempel slag. CRF reseptorantagonistene har formel (I) inkludert stereoisomerer, prodmgs og farmasøytisk akseptable salter derav, der RI, R2, R3, Y, Ar og Het er som angitt i beskrivelsen. Det beskrives videre preparater irmeholdende en CRF reseptorantagonist i kombinasjon med en farmasøytisk akseptabel bærer, så vel som fremgangsmåter for anvendelse derav.
NO20063230A 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav NO20063230L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22
PCT/IB2004/004234 WO2005063755A1 (en) 2003-12-22 2004-12-20 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
NO20063230L true NO20063230L (no) 2006-09-12

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063230A NO20063230L (no) 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav

Country Status (19)

Country Link
US (1) US7737154B2 (no)
EP (1) EP1697374B1 (no)
JP (1) JP4926720B2 (no)
KR (1) KR20070009537A (no)
CN (1) CN1938309B (no)
AR (1) AR046967A1 (no)
AU (1) AU2004309168B2 (no)
BR (1) BRPI0417943A (no)
CA (1) CA2550948A1 (no)
IL (1) IL176350A0 (no)
IS (1) IS8526A (no)
MA (1) MA29984B1 (no)
MY (1) MY143499A (no)
NO (1) NO20063230L (no)
NZ (1) NZ547990A (no)
RU (1) RU2394035C2 (no)
TW (1) TW200530242A (no)
WO (1) WO2005063755A1 (no)
ZA (1) ZA200604574B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
JP5184536B2 (ja) * 2006-09-20 2013-04-17 イーライ リリー アンド カンパニー チオフェンピラゾロピリミジン化合物
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (en) * 2008-04-21 2014-09-10 Albemarle Corporation Processes for producing n-alkylpyrazole
JP5748777B2 (ja) * 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
RU2672722C2 (ru) * 2014-04-10 2018-11-19 Хубэй Био-Фармасьютикал Индастриал Текнолоджикал Инститьют Инк. Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN116829558A (zh) * 2020-07-27 2023-09-29 艾斯法姆生物技术股份有限公司 化合物
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
ATE301657T1 (de) * 1998-01-28 2005-08-15 Bristol Myers Squibb Pharma Co Azolo-pyrimidine
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
DE60225127T2 (de) 2001-04-30 2009-02-19 Glaxo Group Ltd., Greenford Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
EP1395591B1 (en) 2001-06-12 2008-06-04 Glaxo Group Limited Corticotropin releasing factor antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
WO2004062665A1 (en) 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
TW200530242A (en) 2005-09-16
KR20070009537A (ko) 2007-01-18
MY143499A (en) 2011-05-31
IS8526A (is) 2006-07-11
WO2005063755A1 (en) 2005-07-14
AR046967A1 (es) 2006-01-04
CA2550948A1 (en) 2005-07-14
ZA200604574B (en) 2007-11-28
NZ547990A (en) 2010-04-30
AU2004309168A1 (en) 2005-07-14
EP1697374A1 (en) 2006-09-06
US20070287705A1 (en) 2007-12-13
AU2004309168B2 (en) 2009-04-23
CN1938309A (zh) 2007-03-28
BRPI0417943A (pt) 2007-04-17
IL176350A0 (en) 2006-10-05
EP1697374B1 (en) 2012-08-29
JP2007515472A (ja) 2007-06-14
RU2006126675A (ru) 2008-01-27
CN1938309B (zh) 2011-11-09
RU2394035C2 (ru) 2010-07-10
US7737154B2 (en) 2010-06-15
JP4926720B2 (ja) 2012-05-09
MA29984B1 (fr) 2008-12-01

Similar Documents

Publication Publication Date Title
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
HRP20080666T3 (en) Cgrp receptor antagonists
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
TW200626599A (en) CRF receptor antagonists and methods relating thereto
NO20070445L (no) Pyrimidinderivater.
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
GEP20074125B (en) Pyrazolopyridines and methods of making and using the same
WO2004056799A3 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
MX2007007152A (es) Antagonista de naurocinina-1 con anillo en puente.
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
DE60100811D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application